Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2

N/AActive Not RecruitingNCT04227535

Assistance Publique - Hôpitaux de Paris509 enrolled

Overview

The overall goal of this study is to identify risk and prognosis factors of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA).

This is not an interventional study. This is a study designed to recruit individuals affected by RA and investigate associated ILD to better understand the clinical phenotypes and genetic/molecular endotypes of RAILD, including the prognosis of the disease.

Study Type

OBSERVATIONAL

Enrollment

509

Conditions

Rheumatoid Arthritis Interstitial Lung Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

SELECTION OF CASES : Inclusion Criteria: * Age ≥18 years * RA diagnosis according to ACR (classification of rheumatoid arthritis) 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist * ILD diagnosis based on typical High-Resolution Computed-Tomography (HCRT) patterns and pulmonary function tests (PFT), validated by a senior pulmonologist Exclusion Criteria: \- Lack of signed informed consent SELECTION OF CONTROLS: Inclusion Criteria: * Age ≥18 years * RA diagnosis according to ACR 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist Exclusion Criteria: \- Lack of signed informed consent

Locations (1)

Bichat Hospital

Paris, France

Outcomes

Primary Outcomes

Identification of genetic factors implicated in RA-ILD using whole exome sequencing (WES).

whole exome sequencing data

Time frame: Baseline

Secondary Outcomes

Identification of genetic factors implicated in RA-ILD using genome wide association study.

genome wide sequencing data

Time frame: Baseline

Describe RA-ILD natural history by a 5 years annual follow up of RA-ILD patients.

Decline of pulmonary functional tests (PFT) as well as changes in High-Resolution Computed-Tomography chest scan scores

Time frame: Every year during 5 years

Description of the effect of disease modifying Anti Rheumatic Drugs (DMARDs) on ILD course and mortality.

Influence of treatment (DMARDs and biologics) over RA-ILD course estimated annually given the cumulated dosage received.

Time frame: Every year during 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.